Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Celldex Therapeutics Inc. (NASDAQ: CLDX) closed the day trading at $38.53 down -2.78% from the previous closing price of $39.63. In other words, the price has decreased by -$2.78 from its previous closing price. On the day, 0.58 million shares were traded. CLDX stock price reached its highest trading level at $39.8 during the session, while it also had its lowest trading level at $38.31.
Ratios:
For a better understanding of CLDX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.87 and its Current Ratio is at 13.87. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 10, 2023, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight but kept the price unchanged to $27.
On August 22, 2023, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $21.Wells Fargo initiated its Underweight rating on August 22, 2023, with a $21 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 2531370752 and an Enterprise Value of 1732797184. For the stock, the TTM Price-to-Sale (P/S) ratio is 360.77 while its Price-to-Book (P/B) ratio in mrq is 5.02. Its current Enterprise Value per Revenue stands at 251.75 whereas that against EBITDA is -12.463.
Stock Price History:
Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $22.11. The 50-Day Moving Average of the stock is -8.06%, while the 200-Day Moving Average is calculated to be 12.47%.
Shares Statistics:
Over the past 3-months, CLDX traded about 933.49K shares per day on average, while over the past 10 days, CLDX traded about 582310 shares per day. A total of 64.42M shares are outstanding, with a floating share count of 62.84M. Insiders hold about 2.46% of the company’s shares, while institutions hold 94.18% stake in the company. Shares short for CLDX as of 1711584000 were 6557945 with a Short Ratio of 7.03, compared to 1709164800 on 6411060. Therefore, it implies a Short% of Shares Outstanding of 6557945 and a Short% of Float of 11.44.
Earnings Estimates
At present, USCF Gold Strategy Plus Income analysts are actively evaluating the performance of Celldex Therapeutics Inc. (CLDX) in the stock market.The consensus estimate for the next quarter is $25.70, with high estimates of $38.53 and low estimates of $143.20.
